肺癌的分子生物学预后因素研究进展(4)
三、展望:
目前,通过大量的基础研究和临床验证,人们已寻找到了较多的与预后有关的分子生物学指标,但尚未有一种能明确地单独预测预后的经过严格临床验证的指标,这也许和肺癌本身由多因素、多种因子参与有关，因此，进行多指标的联合检测以预测肺癌预后已越来越受到人们的重视，有望今后能筛选出决定各期患者预后的指标，制定新的分子分期，采用目前最有效的手段，实现个体化治疗。针对影响预后的各因子进行靶向治疗已走出实验室并在临床试验中带来鼓舞人心的前景，其最终能给肺癌治疗带来多大益处仍在探讨之中。
参考文献
1.Hollstein M,Sidransky D,Vogelstein B,et al.P53 mutations in human cancers.Science,1991,253:49-53.
2.白莉等.癌变.畸变.突变,1996,8(6);321-326.
3.Hollstein M，Sidransky D,Vogelstein B,et al.P53 mutations in human cancers.Science,1991,253:49-53.
4.Kawasaki M,Nakanishi Y,Kiwano K,et al.The utility of P53 immunostaining of transbronchial biopsy specimens of lung cancer:P53 overexpression predicts poor prognosis and chemoresistance in advance non-small cell lung cancer. Clin Cancer Res,1997,3:1195-2000.
5.Huncharek,M, Kupelnick,B,Geschwind,et al.Prognostic significance of P53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer-Lett. 2000 May 29,153(1-2): 219-26
6.Mitsudomi T,Hamajima N,Ogawa,M,et al. Prognostic significance of P53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin-Cancer-Res. 2000 Oct 6(10): 4055-63
7.Huncharek,M,Muscat,J,Geschwind,-J. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Carcinogenesis. 1999 Aug 20(8): 1507-10
8.Rodenhuiss,Shebos RJ.Clinical significance of ras oncogene activation in human lung cancer.Cancer Res 1992;52(suppl 9):2665.
9.王晓云等.癌变.畸变.突变.1995,7(4):172.
10.Mills NE et al.Cancer Res,1995,55:4243-4247.
11.Kawashimi K,Nomura S,Hirai H,et al.Correlation of L-myc RFLPwith metastasis,prognosis, and multiple cancer in lung cancer patients.Int J Cancer,1992,50:557-561.
12.许凯黎，廖美琳等。非小细胞肺癌分子病理学的研究。中国肺癌杂志。2001,2.20；4(1)：33-36
13.Volm M,Koomaki R,Mattern J.Angiogenic growth factors and their receptors in NSCLC and their relationship to drug response in vitro.Anticancer Res,1997,17(1A):99-103., http://www.100md.com(程超)
目前,通过大量的基础研究和临床验证,人们已寻找到了较多的与预后有关的分子生物学指标,但尚未有一种能明确地单独预测预后的经过严格临床验证的指标,这也许和肺癌本身由多因素、多种因子参与有关，因此，进行多指标的联合检测以预测肺癌预后已越来越受到人们的重视，有望今后能筛选出决定各期患者预后的指标，制定新的分子分期，采用目前最有效的手段，实现个体化治疗。针对影响预后的各因子进行靶向治疗已走出实验室并在临床试验中带来鼓舞人心的前景，其最终能给肺癌治疗带来多大益处仍在探讨之中。
参考文献
1.Hollstein M,Sidransky D,Vogelstein B,et al.P53 mutations in human cancers.Science,1991,253:49-53.
2.白莉等.癌变.畸变.突变,1996,8(6);321-326.
3.Hollstein M，Sidransky D,Vogelstein B,et al.P53 mutations in human cancers.Science,1991,253:49-53.
4.Kawasaki M,Nakanishi Y,Kiwano K,et al.The utility of P53 immunostaining of transbronchial biopsy specimens of lung cancer:P53 overexpression predicts poor prognosis and chemoresistance in advance non-small cell lung cancer. Clin Cancer Res,1997,3:1195-2000.
5.Huncharek,M, Kupelnick,B,Geschwind,et al.Prognostic significance of P53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer-Lett. 2000 May 29,153(1-2): 219-26
6.Mitsudomi T,Hamajima N,Ogawa,M,et al. Prognostic significance of P53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin-Cancer-Res. 2000 Oct 6(10): 4055-63
7.Huncharek,M,Muscat,J,Geschwind,-J. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Carcinogenesis. 1999 Aug 20(8): 1507-10
8.Rodenhuiss,Shebos RJ.Clinical significance of ras oncogene activation in human lung cancer.Cancer Res 1992;52(suppl 9):2665.
9.王晓云等.癌变.畸变.突变.1995,7(4):172.
10.Mills NE et al.Cancer Res,1995,55:4243-4247.
11.Kawashimi K,Nomura S,Hirai H,et al.Correlation of L-myc RFLPwith metastasis,prognosis, and multiple cancer in lung cancer patients.Int J Cancer,1992,50:557-561.
12.许凯黎，廖美琳等。非小细胞肺癌分子病理学的研究。中国肺癌杂志。2001,2.20；4(1)：33-36
13.Volm M,Koomaki R,Mattern J.Angiogenic growth factors and their receptors in NSCLC and their relationship to drug response in vitro.Anticancer Res,1997,17(1A):99-103., http://www.100md.com(程超)